The outbreak of COVID-19 is an unprecedented and rapidly evolving challenge that has prompted many concerns that businesses might exploit the situation to take advantage of people, for example by charging excessive prices or making misleading claims about their products.
In its statement of 5 March, the Competition and Markets Authority (CMA) urged retailers to behave responsibly and said that it would consider any evidence that companies may have broken competition or consumer protection law.
As the public health emergency worsens and its impact on the economy becomes more serious, the CMA is creating a taskforce which will:
- Scrutinise market developments to identify harmful sales and pricing practices as they emerge.
- Warn firms suspected of exploiting these exceptional circumstances – and people’s vulnerability – through unjustifiable prices or misleading claims. The CMA has already contacted traders and platforms regarding excessive pricing of hand sanitiser.
- Take enforcement action if there is evidence that firms may have breached competition or consumer protection law and they fail to respond to warnings…
Featured News
NFL Antitrust Verdict Amounts to $4.7 Billion in ‘Sunday Ticket’ Case
Jul 4, 2024 by
CPI
German Competition Regulator Fines AVM EUR 16 Million for Price-Fixing Scheme
Jul 4, 2024 by
CPI
UK’s CMA Director Returns to Cleary Gottlieb as Antitrust Partner
Jul 4, 2024 by
CPI
Canada’s Competition Bureau to Expedite Guidance on Anti-Greenwashing Rules
Jul 4, 2024 by
CPI
Top Lawyers Face Off in Tempur Sealy’s Bid for Mattress Firm
Jul 4, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI